Evidence map›Paper›PMID 28504724›Full record

ArticleNature medicine2017

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Alice Giustacchini, Supat Thongjuea, Nikolaos Barkas, Petter S Woll, Benjamin J Povinelli, Christopher A G Booth, Paul Sopp, Ruggiero Norfo, Alba Rodriguez-Meira, Neil Ashley and 10 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 259 papers.

0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed
32.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

259 citing papers in PubMed, 416 citations in OpenAlex.

  1. Trial
  2. Article
  3. Oxidative Phosphorylation and Fatty Acid Oxidation Are Central to Mitochondrial Metabolism Rewiring in CML Stem/Progenitor Cell Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Epigenetic regulation of cancer stemness.Signal transduction and targeted therapy · 2025
    Review

199 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 4 countries.

Alice GiustacchiniMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-8733-8594
Supat ThongjueaMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Nikolaos BarkasMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Petter S WollHaemopoietic Stem Cell Biology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Benjamin J PovinelliMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Christopher A G BoothMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Paul SoppMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Ruggiero NorfoMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Alba Rodriguez-MeiraMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Neil AshleyMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Lauren JamiesonMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Paresh VyasMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3931-0914
Kristina AndersonDepartment of Cellular Therapy, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Åsa SegerstolpeDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Hong QianDepartment of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-2512-9199
Ulla Olsson-StrömbergDepartment of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden.
Satu MustjokiHematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Rickard SandbergDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-6473-1740
Sten Eirik W JacobsenMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Adam J MeadMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-8522-1002
University of Oxford · GBKarolinska Institutet · SEChurchill Hospital · GBKarolinska University Hospital · SEOslo University Hospital · NOUniversity of Helsinki · FIUppsala University Hospital · SE

Funding

Medical Research Council G0501838Medical Research Council G0801073Medical Research Council G0902418Medical Research Council G1000729Medical Research Council MC_PC_12020Medical Research Council MC_PC_13073Medical Research Council MC_U137961145Medical Research Council MC_UU_00016/5Medical Research Council MC_UU_12009/11Medical Research Council MC_UU_12009/5Medical Research Council MR/L006340/1Medical Research Council MR/L008963/1Medical Research Council MR/M00919X/1
6 · The paper itself

Abstract

Recent advances in single-cell transcriptomics are ideally placed to unravel intratumoral heterogeneity and selective resistance of cancer stem cell (SC) subpopulations to molecularly targeted cancer therapies. However, current single-cell RNA-sequencing approaches lack the sensitivity required to reliably detect somatic mutations. We developed a method that combines high-sensitivity mutation detection with whole-transcriptome analysis of the same single cell. We applied this technique to analyze more than 2,000 SCs from patients with chronic myeloid leukemia (CML) throughout the disease course, revealing heterogeneity of CML-SCs, including the identification of a subgroup of CML-SCs with a distinct molecular signature that selectively persisted during prolonged therapy. Analysis of nonleukemic SCs from patients with CML also provided new insights into cell-extrinsic disruption of hematopoiesis in CML associated with clinical outcome. Furthermore, we used this single-cell approach to identify a blast-crisis-specific SC population, which was also present in a subclone of CML-SCs during the chronic phase in a patient who subsequently developed blast crisis. This approach, which might be broadly applied to any malignancy, illustrates how single-cell analysis can identify subpopulations of therapy-resistant SCs that are not apparent through cell-population analysis.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticSingle-Cell AnalysisAdultAgedBlast CrisisChromatin ImmunoprecipitationCore Binding Factor Alpha 2 SubunitFemaleFlow CytometryGene LibraryGenes, ablHumansIn Situ Hybridization, FluorescenceLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleCore Binding Factor Alpha 2 SubunitRUNX1 protein, human

Identifiers

PMID28504724
OpenAlexW2614253029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.